Please find below the results of your literature search request.

If you would like the full text of any of the abstracts included, or would like a further search completed on this topic, please let us know.

We’d appreciate feedback on your satisfaction with this literature search. Please visit http://www.hello.nhs.uk/literature_search_feedback.asp and complete the form.

Thank you

**Literature search results**

**Search completed for:**

**Search required by:** 30 June 2012

**Search completed on:** 28 June 2012

**Search completed by:** Richard Bridgen

### Management details

Management of mastocytosis. Details of management of cutaneous and systemic forms of the condition.

### Resources searched

NHS Evidence; TRIP Database; Cochrane Library; CINAHL; EMBASE; MEDLINE; Google Scholar

**Database search terms:** mastocyto*; exp MASTOCYТОМА; exp MASTOCYTOSIS; “diffuse mastocytosis”; diffuse adj2 mastocytosis; “diffuse cutaneous mastocytosis”;

“systemic mastocytosis”; exp MASTOCYTOSIS, CUTANEOUS; exp MASTOCYTOSIS, SYSTEMIC; leukemia adj2 mast-cell; leukemia adj2 “mast cell”; leukemia adj2 mast-cell; leukaemia adj2 mast-cell; leukaemia adj2 “mast cell”; leukaemia adj2 mast-cell; urticarial adj2 pigmentosa; mastocytoma adj2 skin; “mast cell” adj2 diffuse “mast cell” adj2 cutaneous; “mast cell” adj2 systemic; therap*; treatment*; intervention*; manage*; exp THERAPEUTICS; exp THERAPY; adult; exp ADULTS; aged; exp AGED; senior*; elder*; “older people”; “older person”

**NHS Evidence search strings:** "diffuse cutaneous mastocytosis" OR "diffuse mastocytosis" OR "systemic mastocytosis" OR "mast-cell leukaemia" OR "mast-cell leukemia" OR "urticaria pigmentosa" OR "mastocytoma of the skin" OR "skin mastocytoma"

(mastocyto* ("diffuse cutaneous" OR diffuse OR systemic)) OR "mast-cell leukaemia" OR "mast-cell leukemia" OR "urticaria pigmentosa" OR "mastocytoma of the skin" OR "skin mastocytoma"

**Google search string:** (~"diffuse cutaneous mastocytosis" OR ~"diffuse mastocytosis" OR ~"systemic mastocytosis" OR ~"mast-cell leukemia" OR ~"urticaria pigmentosa") (~therapy OR ~treatment OR ~intervention OR ~management)
Summary

There is a huge amount of research on mastocytosis, even in the specific forms you indicated. I have therefore concentrated on the management of cutaneous and systemic mastocytosis and omitted anything dealing with the treatment of conditions where the patient already has mastocytosis, aetiology, incidence, prognosis and diagnosis.

Guidelines

British Association of Dermatologists


There is a paucity of evidence concerning the efficacy of bath PUVA in other dermatoses, although there are reports (Table 1a) of its value in lichen planus, systemic sclerosis and generalized morphea, urticaria pigmentosa, mycosis fungoides, polymorphic light eruption, prurigo simplex subacuta, nodular prurigo, aquagenic pruritus and lymphomatoid papulosis.

In the absence of controlled studies to examine the efficacy of bath PUVA in generalized disorders other than chronic plaque psoriasis, we suggest that a common sense approach is to try a course of bath PUVA in the above conditions if other measu

Evidence-based reviews

CancerHelp UK

Acute myeloid leukaemia research 2012

Another trial is looking at a tyrosine kinase inhibitor drug called midostaurin (also known as PKC412) for people who have mast cell leukaemia (a very rare type of AML). The trial aims to find out if midostaurin helps people with mast cell leukaemia and to learn about how it works and its side effects.

Clinical Immediate Reference

Mastocytosis and Mast Cell Disorders 2011

New Drugs Online

Midostaurin

Published research


Citation: Journal of Clinical Oncology, April 2012, vol./is. 30/12(e126-9), 0732-183X;1527-7755 (2012 Apr 20)

Publication Date: April 2012

Source: Medline

Available in fulltext at the ULHT Library and Knowledge Services’ eJournal collection


Author(s) Pardanani A
3. Indolent systemic mastocytosis treated with narrow-band UVB phototherapy: Study of five cases

Author(s) Brazzelli V., Grasso V., Manna G., Barbaccia V., Merante S., Boveri E., Borroni G.

Citation: Journal of the European Academy of Dermatology and Venereology, April 2012, vol./is. 26/4(465-469), 0926-9959;1468-3083 (April 2012)

Publication Date: April 2012

Source: EMBASE

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

4. Urticaria pigmentosa after treatment with TNF antagonists: A case report

Author(s) Leloup P., Daviet V., Chiffoleau A., Dreno B.

Citation: Archives of Dermatology, December 2011, vol./is. 147/12(1459-1460), 0003-987X;1538-3652 (December 2011)

Publication Date: December 2011

Source: EMBASE

Available in fulltext at Highwire Press

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

5. Urticaria pigmentosa after treatment with TNF antagonists: a case report.

Author(s) Leloup P, Daviet V, Chiffoleau A, Dreno B

Citation: Archives of Dermatology, December 2011, vol./is. 147/12(1459-60), 0003-987X;1538-3652 (2011 Dec)

Publication Date: December 2011

Source: Medline

Available in fulltext at Highwire Press

Available in print at ULHT journal article requests. Complete the online form to obtain articles.


Citation: Experimental Hematology, August 2011, vol./is. 39/8(859-65.e2), 0301-472X;1873-2399 (2011 Aug)

Publication Date: August 2011

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.
7. Interferon alpha and pamidronate in osteoporosis with fracture secondary to mastocytosis.

**Author(s)** Laroche M, Livideanu C, Paul C, Cantagrel A

**Citation:** American Journal of Medicine, August 2011, vol./is. 124/8(776-8), 0002-9343;1555-7162 (2011 Aug)

**Publication Date:** August 2011

**Source:** Medline

*Available in print at ULHT journal article requests. Complete the online form to obtain articles.*

8. Imatinib mesylate for aggressive systemic mastocytosis with long bone osteolysis.

**Author(s)** Jung AG, Horny HP, Sotlar K, Overbeck T, Schon MP, Lippert U

**Citation:** Journal of the American Academy of Dermatology, July 2011, vol./is. 65/1(224-6), 0190-9622;1097-6787 (2011 Jul)

**Publication Date:** July 2011

**Source:** Medline

*Available in fulltext at the ULHT Library and Knowledge Services' eJournal collection*.

9. A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.

**Author(s)** Mital A, Piskorz A, Lewandowski K, Wasag B, Limon J, Hellmann A

**Citation:** European Journal of Haematology, June 2011, vol./is. 86/6(531-5), 0902-4441;1600-0609 (2011 Jun)

**Publication Date:** June 2011

**Source:** Medline

*Available in fulltext at EBSCOhost*

*Available in print at ULHT journal article requests. Complete the online form to obtain articles.*


**Author(s)** Radojkovic M, Ristic S, Colovic N, Terzic T, Colovic M

**Citation:** Vojnosanitetski Pregled, May 2011, vol./is. 68/5(444-6), 0042-8450;0042-8450 (2011 May)

**Publication Date:** May 2011

**Source:** Medline

*Available in fulltext at EBSCOhost*

*Available in print at ULHT journal article requests. Complete the online form to obtain articles.*

11. Response to cladribine in patient with systemic mastocytosis [English;Bosnian] Primena kladribina u lecenju bolesnika sa sistemskom mastocitozom

**Author(s)** Radojkovic M., Ristic S., Colovic N., Terzic T., Colovic M.
12. A global phase II, single-arm, open-label study to determine the efficacy of midostaurin in patients with aggressive systemic mastocytosis (ASM) or mast cell leukemia (MCL) with or without an associated hematologic clonal nonmast cell lineage disease (AHNMD)


Citation: Journal of Clinical Oncology, May 2011, vol./is. 29/15 SUPPL. 1, 0732-183X (20 May 2011)

Publication Date: May 2011

Source: EMBASE

Available in fulltext at the ULHT Library and Knowledge Services' eJournal collection


Author(s) Pardanani A

Citation: American Journal of Hematology, April 2011, vol./is. 86/4(362-71), 0361-8609;1096-8652 (2011 Apr)

Publication Date: April 2011

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.


Author(s) Matito A, Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, Orfao A, Escribano L

Citation: International Archives of Allergy & Immunology, 2011, vol./is. 156/1(104-11), 1018-2438;1423-0097 (2011)

Publication Date: 2011

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

15. Unpredicted adverse reaction to omalizumab.

Author(s) Jandus P, Hausmann O, Haeberli G, Gentinetta T, Mueller U, Helbling A

Citation: Journal of Investigational Allergology & Clinical Immunology, 2011, vol./is. 21/7(563-6), 1018-9068;1018-9068 (2011)

Publication Date: 2011
16. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases.

Author(s) Molderings GJ, Raithel M, Kratz F, Azemar M, Haenisch B, Harzer S, Homann J

Citation: Internal Medicine, 2011, vol./is. 50/6(611-5), 0918-2918;1349-7235 (2011)

Publication Date: 2011

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

17. Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a study

Author(s) Paul C., Sans B., Suarez F., Casassus P., Barete S., Lanternier F., Grandpeix-Guyodo C., Dubreuil P., Palmerini F., Mansfield C.D., Gineste P., Moussy A., Hermine O., Lortholary O.

Citation: American Journal of Hematology, December 2010, vol./is. 85/12(921-925), 0361-8609;1096-8652 (December 2010)

Publication Date: December 2010

Source: EMBASE

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

18. Cutaneous mastocytosis: Successful treatment with narrowband ultraviolet B phototherapy

Author(s) Prignano F., Troiano M., Lotti T.

Citation: Clinical and Experimental Dermatology, December 2010, vol./is. 35/8(914-915), 0307-6938;1365-2230 (December 2010)

Publication Date: December 2010

Source: EMBASE

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

19. Long term efficacy and safety of cladribine in adult systemic mastocytosis: A French multicenter study of 44 patients

Author(s) Hermine O., Hirsh I., Damaj G., Granpeix C., Barete S., Suarez F., Chansderis O., Ghez D., Delarue R., Lanternier F., Deau B., Coignon H., Fraitag S., Canioni D., Casassus P., Dubreuil P., Lortholary O.

Citation: Blood, November 2010, vol./is. 116/21, 0006-4971 (19 Nov 2010)

Publication Date: November 2010

Source: EMBASE

Available in fulltext at Highwire Press

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

**Author(s)** Yunaev M, Hughes TM, Abdul-Razak M

**Citation:** ANZ Journal of Surgery, November 2010, vol./is. 80/11(860-1), 1445-1433;1445-2197 (2010 Nov)

**Publication Date:** November 2010

**Source:** Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.


**Author(s)** Yoong J, Le B

**Citation:** Internal Medicine Journal, October 2010, vol./is. 40/10(735-6), 1444-0903;1445-5994 (2010 Oct)

**Publication Date:** October 2010

**Source:** Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

22. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.


**Citation:** Experimental Hematology, September 2010, vol./is. 38/9(744-55), 0301-472X;1873-2399 (2010 Sep)

**Publication Date:** September 2010

**Source:** Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

23. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient

**Author(s)** Douglass J.A., Carroll K., Voskamp A., Bourke P., Wei A., O’Hehir R.E.

**Citation:** Allergy: European Journal of Allergy and Clinical Immunology, July 2010, vol./is. 65/7(926-927), 0105-4538;1398-9995 (July 2010)

**Publication Date:** July 2010

**Source:** EMBASE

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

24. Treatment of aggressive systemic mastocytosis with daclizumab.

**Author(s)** Quintas-Cardama A, Amin HM, Kantarjian H, Verstovsek S

**Citation:** Leukemia & Lymphoma, March 2010, vol./is. 51/3(540-2), 1026-8022;1029-2403
<table>
<thead>
<tr>
<th></th>
<th>Publication Date: March 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source:</strong></td>
<td>Medline</td>
</tr>
<tr>
<td>Available in fulltext at</td>
<td>EBSCOhost</td>
</tr>
<tr>
<td>Available in print at</td>
<td>ULHT journal article requests. Complete the online form to obtain articles.</td>
</tr>
</tbody>
</table>

**25. Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature.**

**Author(s):** Pardanani A, Tefferi A  
**Citation:** Current Opinion in Hematology, 01 March 2010, vol./is. 17/2(125-132), 10656251

<table>
<thead>
<tr>
<th></th>
<th>Publication Date: 01 March 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source:</strong></td>
<td>CINAHL</td>
</tr>
<tr>
<td>Available in print at</td>
<td>ULHT journal article requests. Complete the online form to obtain articles.</td>
</tr>
</tbody>
</table>

**26. Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis.**

**Author(s):** Parikh SA, Kantarjian HM, Richie MA, Cortes JE, Verstovsek S  
**Citation:** Leukemia & Lymphoma, February 2010, vol./is. 51/2(269-74), 1026-8022;1029-2403 (2010 Feb)

<table>
<thead>
<tr>
<th></th>
<th>Publication Date: February 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source:</strong></td>
<td>Medline</td>
</tr>
<tr>
<td>Available in fulltext at</td>
<td>EBSCOhost</td>
</tr>
<tr>
<td>Available in print at</td>
<td>ULHT journal article requests. Complete the online form to obtain articles.</td>
</tr>
</tbody>
</table>

**27. Oral and inhaled sodium cromoglicate in the management of systemic mastocytosis: A case report**

**Author(s):** Edwards A.M., Hagberg H.  
**Citation:** Journal of Medical Case Reports, 2010, vol./is. 4/, 1752-1947;1 752-1947 (2010)

<table>
<thead>
<tr>
<th></th>
<th>Publication Date: 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source:</strong></td>
<td>EMBASE</td>
</tr>
<tr>
<td>Available in fulltext at</td>
<td>BioMedCentral</td>
</tr>
<tr>
<td>Available in fulltext at</td>
<td>National Library of Medicine</td>
</tr>
<tr>
<td>Available in print at</td>
<td>ULHT journal article requests. Complete the online form to obtain articles.</td>
</tr>
</tbody>
</table>

**28. Systemic mastocytosis associated with the c-KIT D816V mutation-importance of molecular diagnosis and therapeutic implications. case report**

**Author(s):** Trifa A.P., Patiu M., Cucuianu A., Dima D., Militaru M.S., Pop I.V., Popp R.A.  
**Citation:** Timisoara Medical Journal, 2010, vol./is. 60/2-3(241-243), 1583-5251;1583-526X (2010)

<table>
<thead>
<tr>
<th></th>
<th>Publication Date: 2010</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Source:</strong></td>
<td>EMBASE</td>
</tr>
<tr>
<td>Article Title</td>
<td>Author(s)</td>
</tr>
<tr>
<td>------------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>29. Current approaches to the diagnosis and treatment of systemic mastocytosis.</td>
<td>Bains SN, Hsieh FH</td>
</tr>
</tbody>
</table>
34. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V.

**Author(s)** Ustun C, Corless CL, Savage N, Fiskus W, Manaloor E, Heinrich MC, Lewis G, Ramalingam P, Kepten I, Jillella A, Bhalla K

**Citation:** Leukemia Research, May 2009, vol./is. 33/5(735-41), 0145-2126;1873-5835 (2009 May)

**Publication Date:** May 2009

**Source:** Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

35. Adult onset Urticaria pigmentosa: A case report

**Author(s)** Prabhu S., Rao R., Sripathi H., Kudva R.

**Citation:** Journal of Pakistan Association of Dermatologists, April 2009, vol./is. 19/2(115-117), 1560-9014 (April-June 2009)

**Publication Date:** April 2009

**Source:** EMBASE

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

36. Hereditary cutaneous mastocytosis

**Author(s)** Fett N., Longley J., Teng J.

**Citation:** Journal of the American Academy of Dermatology, March 2009, vol./is. 60/3 SUPPL. 1(AB61-AB62), 0190-9622 (March 2009)

**Publication Date:** March 2009

**Source:** EMBASE

Available in fulltext at the ULHT Library and Knowledge Services' eJournal collection

37. Lenalidomide therapy in systemic mastocytosis.

**Author(s)** Kluin-Nelemans HC, Ferenc V, van Doormaal JJ, van Iperen C, Peters WG, Akin C, Valent P

**Citation:** Leukemia Research, March 2009, vol./is. 33/3(e19-22), 0145-2126;1873-5835 (2009 Mar)

**Publication Date:** March 2009

**Source:** Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

38. Cutaneous mastocytosis localized to a radiotherapy field.

Author(s) Bunimovich O, Grassi M, Baer MR

Citation: Cutis, January 2009, vol./is. 83/1(29-36), 0011-4162;0011-4162 (2009 Jan)

Publication Date: January 2009

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

40. Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.

Author(s) Yoshida C, Takeuchi M, Tsuchiyama J, Sadahira Y

Citation: Internal Medicine, 2009, vol./is. 48/22(1973-8), 0918-2918;1349-7235 (2009)

Publication Date: 2009

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

41. Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.

Author(s) Aichberger KJ, Sperr WR, Gleixner KV, Kretschmer A, Valent P

Citation: European Journal of Clinical Investigation, November 2008, vol./is. 38/11(869-73), 0014-2972;1365-2362 (2008 Nov)

Publication Date: November 2008

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

42. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D2 production.

Author(s) Butterfield J.H., Weiler C.R.

Citation: International Archives of Allergy and Immunology, November 2008, vol./is. 147/4(338-343), 1018-2438 (November 2008)

Publication Date: November 2008

Source: EMBASE

Available in fulltext at EBSCOhost
<table>
<thead>
<tr>
<th>Article Number</th>
<th>Title</th>
<th>Author(s)</th>
<th>Citation</th>
<th>Publication Date</th>
<th>Source</th>
<th>Fulltext Availability</th>
<th>Print Availability</th>
</tr>
</thead>
</table>
47. High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.

Author(s) Kontou-Fili K

Citation: Allergy, March 2008, vol./is. 63/3(376-8), 0105-4538;1398-9995 (2008 Mar)

Publication Date: March 2008

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

48. Efficacy of UVA1 phototherapy in 230 patients with various skin diseases.

Author(s) Rombold S, Lobisch K, Katzer K, Grazziotin TC, Ring J, Eberlein B

Citation: Photodermatology, Photoimmunology & Photomedicine, February 2008, vol./is. 24/1(19-23), 0905-4383;0905-4383 (2008 Feb)

Publication Date: February 2008

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

49. Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion


Citation: Haematologica, January 2008, vol./is. 93/1(49-56), 0390-6078 (January 2008)

Publication Date: January 2008

Source: EMbase

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

Available in fulltext at Highwire Press

50. Treatment of systemic mastocytosis with denileukin diftitox.

Author(s) Quintas-Cardama A, Kantarjian H, Verstovsek S

Citation: American Journal of Hematology, December 2007, vol./is. 82/12(1124), 0361-8609;0361-8609 (2007 Dec)

Publication Date: December 2007

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

51. Treatment of systemic mastocytosis with denileukin diftitox [5]

Author(s) Quintas-Cardama A., Kantarjian H., Verstovsek S.

Citation: American Journal of Hematology, December 2007, vol./is. 82/12(1124), 0361-8609;1096-8652 (December 2007)

Publication Date: December 2007
52. Systemic Mastocytosis: Documented pathologic response to imatinib

Author(s) Gollard R.P., Ruemmler-Fish C., Garcia D.

Citation: European Journal of Haematology, October 2007, vol./is. 79/4(367-368), 0902-4441;1600-0609 (October 2007)

Publication Date: October 2007

Source: EMBASE

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

53. Successful treatment of cutaneous mastocytosis and Meniere disease with anti-IgE therapy.

Author(s) Siebenhaar F, Kuhn W, Zuberbier T, Maurer M

Citation: Journal of Allergy & Clinical Immunology, July 2007, vol./is. 120/1(213-5), 0091-6749;0091-6749 (2007 Jul)

Publication Date: July 2007

Source: Medline

Available in fulltext at the ULHT Library and Knowledge Services' eJournal collection

Available in print at ULHT journal article requests. Complete the online form to obtain articles.


Author(s) Carter MC, Robyn JA, Bressler PB, Walker JC, Shapiro GG, Metcalfe DD

Citation: Journal of Allergy & Clinical Immunology, June 2007, vol./is. 119/6(1550-1), 0091-6749;0091-6749 (2007 Jun)

Publication Date: June 2007

Source: Medline

Available in fulltext at the ULHT Library and Knowledge Services' eJournal collection

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

55. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.

Author(s) Nakagomi N, Hirot S

Citation: Laboratory Investigation, April 2007, vol./is. 87/4(365-71), 0023-6837;0023-6837 (2007 Apr)

Publication Date: April 2007

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.
56. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutation.

**Author(s)** Dalal BI, Horsman DE, Bruyere H, Forrest DL

**Citation:** American Journal of Hematology, January 2007, vol./is. 82/1(77-9), 0361-8609:0361-8609 (2007 Jan)

**Publication Date:** January 2007

**Source:** Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

57. Efficacy of 25% diluted fluticasone propionate 0.05% cream as wet-wrap treatment in cutaneous mastocytosis.

**Author(s)** Heide R, de Waard-van der Spek FB, den Hollander JC, Tank B, Oranje AP

**Citation:** Dermatology, 2007, vol./is. 214/4(333-5), 1018-8665;1421-9832 (2007)

**Publication Date:** 2007

**Source:** Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

58. Imatinib mesylate responsiveness in aggressive systemic mastocytosis: Novel association with a platelet derived growth factor receptor beta mutation

**Author(s)** Dalal B.I., Horsman D.E., Bruyere H., Forrest D.L.

**Citation:** American Journal of Hematology, January 2007, vol./is. 82/1(77-79), 0361-8609:1096-8652 (January 2007)

**Publication Date:** January 2007

**Source:** EMBASE

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

59. UVA1 phototherapy for cutaneous diseases: An experience of 92 cases in the United States

**Author(s)** Tuchinda C., Kerr H.A., Taylor C.R., Jacobe H., Bergamo B.M., Elmets C., Rivard J., Lim H.W.

**Citation:** Photodermatology Photoimmunology and Photomedicine, October 2006, vol./is. 22/5(247-253), 0905-4383;1600-0781 (October 2006)

**Publication Date:** October 2006

**Source:** EMBASE

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

60. Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response
61. Treatment of systemic mastocytosis.

**Author(s)** Wilson TM, Metcalfe DD, Robyn J

**Citation:** Immunology & Allergy Clinics of North America, 01 August 2006, vol./is. 26/3(549-573), 08898561

**Publication Date:** 01 August 2006

**Source:** CINAHL

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

62. KIT mutations in mastocytosis and their potential as therapeutic targets.

**Author(s)** Gotlib J

**Citation:** Immunology & Allergy Clinics of North America, 01 August 2006, vol./is. 26/3(575-592), 08898561

**Publication Date:** 01 August 2006

**Source:** CINAHL

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

63. Imatinib mesylate in the treatment of systemic mastocytosis: A phase II trial

**Author(s)** Droogendijk H.J., Kluin-Nelemans H.J.C., Van Doormaal J.J., Oranje A.P., Van De Loosdrecht A.A., Van Daele P.L.A.

**Citation:** Cancer, July 2006, vol./is. 107/2(345-351), 0008-543X;1097-0142 (15 Jul 2006)

**Publication Date:** July 2006

**Source:** EMBASE

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

64. A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis.

**Author(s)** Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ

**Citation:** Bone Marrow Transplantation, February 2006, vol./is. 37/4(353-8), 0268-3369;0268-3369 (2006 Feb)

**Publication Date:** February 2006
65. First case of an AIDS patient with systemic mast cell disease associated with FIP1-positive eosinophilia treated with imatinib mesylate therapy.

**Author(s)** Merante S, Chichino G, Boveri E, Gottardi E, Soverini S, Cilloni D, Martinelli G

**Citation:** Journal of Clinical Oncology, February 2006, vol./is. 24/4(e6-7), 0732-183X;1527-7755 (2006 Feb 1)

**Publication Date:** February 2006

**Source:** Medline

Available in fulltext at EBSCOhost
Available in print at ULHT journal article requests. Complete the online form to obtain articles.

66. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: Comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects


**Citation:** Blood, January 2006, vol./is. 107/2(752-759), 0006-4971;0006-4971 (15 Jan 2006)

**Publication Date:** January 2006

**Source:** EMBASE

Available in fulltext at Highwire Press
Available in print at ULHT journal article requests. Complete the online form to obtain articles.

67. Mast cell leukaemia

**Author(s)** Penack O., Thiel E., Notter M.

**Citation:** British Journal of Haematology, November 2005, vol./is. 131/4(416), 0007-1048;1365-2141 (November 2005)

**Publication Date:** November 2005

**Source:** EMBASE

Available in fulltext at EBSCOhost
Available in print at ULHT journal article requests. Complete the online form to obtain articles.

68. Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia [3]

**Author(s)** Penack O., Sotlar K., Noack F., Horny H.-P., Thiel E., Notter M.

**Citation:** Annals of Hematology, October 2005, vol./is. 84/10(692-693), 0939-5555 (October 2005)

**Publication Date:** October 2005

**Source:** EMBASE

Available in fulltext at EBSCOhost
Available in print at ULHT journal article requests. Complete the online form to obtain articles.

Author(s) Penack O, Sotlar K, Noack F, Horny HP, Thiel E, Notter M

Citation: Annals of Hematology, October 2005, vol./is. 84/10(692-3), 0939-5555;0939-5555 (2005 Oct)

Publication Date: October 2005

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

70. Systemic mastocytosis: A rare cause of osteoporosis and its response to bisphosphonate treatment

Author(s) Lim A.Y.N., Ostor A.J.K., Love S., Crisp A.J.

Citation: Annals of the Rheumatic Diseases, June 2005, vol./is. 64/6(965-966), 0003-4967 (June 2005)

Publication Date: June 2005

Source: EMBASE

Available in fulltext at Highwire Press

Available in fulltext at Highwire Press

Available in fulltext at National Library of Medicine

Available in print at ULHT journal article requests. Complete the online form to obtain articles.


Author(s) Hein MS, Hansen L

Citation: South Dakota Journal of Medicine, March 2005, vol./is. 58/3(95-100), 0038-3317;0038-3317 (2005 Mar)

Publication Date: March 2005

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.


Author(s) Butterfield JH, Tefferi A, Kozuh GF

Citation: Leukemia Research, February 2005, vol./is. 29/2(131-4), 0145-2126;0145-2126 (2005 Feb)

Publication Date: February 2005

Source: Medline

Available in print at ULHT journal article requests. Complete the online form to obtain articles.
73. Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.

**Author(s)** Hennessy B, Giles F, Cortes J, O'brien S, Ferrajoli A, Ossa G, Garcia-Manero G, Faderl S, Kantarjian H, Verstovsek S

**Citation:** American Journal of Hematology, November 2004, vol./is. 77/3(209-14), 0361-8609;0361-8609 (2004 Nov)

**Publication Date:** November 2004

**Source:** Medline

Available *in print* at ULHT journal article requests. Complete the online form to obtain articles.

74. The effect of cutaneous mast cell degranulation on sensitivity to heat.

**Author(s)** Drummond PD

**Citation:** Inflammation Research, July 2004, vol./is. 53/7(309-15), 1023-3830;1023-3830 (2004 Jul)

**Publication Date:** July 2004

**Source:** Medline

Available *in print* at ULHT journal article requests. Complete the online form to obtain articles.

75. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib

**Author(s)** Akin C., Fumo G., Yavuz A.S., Lipsky P.E., Neckers L., Metcalfe D.D.

**Citation:** Blood, April 2004, vol./is. 103/8(3222-3225), 0006-4971 (15 Apr 2004)

**Publication Date:** April 2004

**Source:** EMBASE

Available *in fulltext* at Highwire Press

Available *in print* at ULHT journal article requests. Complete the online form to obtain articles.

76. Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: Report of five cases and review of the literature

**Author(s)** Hauswirth A.W., Simonitsch-Klupp I., Uffmann M., Koller E., Sperr W.R., Lechner K., Valent P.

**Citation:** Leukemia Research, March 2004, vol./is. 28/3(249-257), 0145-2126 (March 2004)

**Publication Date:** March 2004

**Source:** EMBASE

Available *in print* at ULHT journal article requests. Complete the online form to obtain articles.

77. Leukotriene-receptor inhibition for the treatment of systemic mastocytosis.

**Author(s)** Tolar J, Tope WD, Neglia JP

**Citation:** New England Journal of Medicine, 12 February 2004, vol./is. 350/7(735-736), 00284793
78. Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine

Author(s) Pardanani A., Hoffbrand A.V., Butterfield J.H., Tefferi A.

Citation: Leukemia Research, February 2004, vol./is. 28/2(127-131), 0145-2126 (February 2004)

Publication Date: February 2004

Source: EMBASE

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

79. Clinical, genetic, and therapeutic insights into systemic mast cell disease.

Author(s) Tefferi A, Pardanani A

Citation: Current Opinion in Hematology, January 2004, vol./is. 11/1(58-64), 1065-6251;1065-6251 (2004 Jan)

Publication Date: January 2004

Source: Medline

Available in fulltext at Ovid

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

80. Cladribine therapy for systemic mastocytosis.

Author(s) Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van 't Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG, Fijnheer R

Citation: Blood, December 2003, vol./is. 102/13(4270-6), 0006-4971;0006-4971 (2003 Dec 15)

Publication Date: December 2003

Source: Medline

Available in fulltext at Highwire Press

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

81. CHIC2 deletion, a surrogate for FIP1L1-PDGFRα fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Author(s) Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A

Citation: Blood, November 2003, vol./is. 102/9(3093-6), 0006-4971;0006-4971 (2003 Nov
1) **Publication Date:** November 2003  
**Source:** Medline  
Available in fulltext at Highwire Press  
Available in print at ULHT journal article requests. Complete the online form to obtain articles.

82. **Medium- versus high-dose ultraviolet A1 therapy for urticaria pigmentosa: a pilot study.**  
**Author(s):** Gobello T, Mazzanti C, Sordi D, Annessi G, Abeni D, Chinni LM, Girolomoni G  
**Citation:** Journal of the American Academy of Dermatology, October 2003, vol./is. 49/4(679-84), 0190-9622;0190-9622 (2003 Oct)  
**Publication Date:** October 2003  
**Source:** Medline  
Available in fulltext at the ULHT Library and Knowledge Services’ eJournal collection  
Available in print at Pilgrim Hospital Staff Library

83. **Imatinib for systemic mast-cell disease.**  
**Author(s):** Pardanani A, Elliott M, Reeder T, Li CY, Baxter EJ, Cross NC, Tefferi A  
**Citation:** Lancet, August 2003, vol./is. 362/9383(535-6), 0140-6736;1474-547X (2003 Aug 16)  
**Publication Date:** August 2003  
**Source:** Medline  
Available in print at ULHT journal article requests. Complete the online form to obtain articles.  
Available in fulltext at EBSCOhost  
Available in print at Grantham Hospital Staff Library  
Available in print at ULHT journal article requests. Complete the online form to obtain articles.  
Available in print at Louth County Hospital Medical Library  
Available in print at Pilgrim Hospital Staff Library  
Available in print at Lincoln County Hospital Professional Library

84. **Aggressive systemic mastocytosis**  
**Author(s):** Inaoui R., Petit B., Jaccard A., Bertin P., Treves R.  
**Citation:** Joint Bone Spine, February 2003, vol./is. 70/1(64-66), 1297-319X (February 2003)  
**Publication Date:** February 2003  
**Source:** EMBASE

85. **Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients.**  
**Citation:** British Journal of Haematology, December 2002, vol./is. 119/4(1090-7), 0007-
86. Treatment of systemic mast-cell disease with cladribine [3]

Author(s) Tefferi A., Li C.-Y., Butterfield J.H., Hoagland H.C.

Citation: New England Journal of Medicine, January 2001, vol./is. 344/4(307-309), 0028-4793 (25 Jan 2001)

Publication Date: January 2001

Source: EMBASE

Available in fulltext at EBSCOhost

Available in print at Grantham Hospital Staff Library

Available in fulltext at the ULHT Library and Knowledge Services' eJournal collection

Available in print at Pilgrim Hospital Staff Library

87. Effects of interferon-alpha2b treatment on ex vivo differentiation of mast cells from circulating progenitor cells in a patient with systemic mastocytosis.


Citation: Annals of Hematology, December 2000, vol./is. 79/12(660-6), 0939-5555;0939-5555 (2000 Dec)

Publication Date: December 2000

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

88. The treatment of urticaria pigmentosa with the frequency-doubled Q-switch Nd:YAG laser.

Author(s) Bedlow AJ, Gharrie S, Harland CC

Citation: Journal of Cutaneous Laser Therapy, March 2000, vol./is. 2/1(45-7), 1462-883X;1462-883X (2000 Mar)

Publication Date: March 2000

Source: Medline

Available in fulltext at EBSCOhost

Available in print at ULHT journal article requests. Complete the online form to obtain articles.

Google Scholar

From 1st 50 results…

Diagnosis and treatment of systemic mastocytosis: state of the art
Mastocytosis: current concepts in diagnosis and treatment

A Quintas-Cardama, A Aribi, J Cortes, FJ Giles... - Cancer, 2006 - Wiley Online Library
In the absence of curative options, therapy for aggressive forms of systemic mastocytosis (SM) has relied on the use of cytoreductive agents, mainly interferon-α (IFN-α) and cladribine. However, responses are transient and only occur in a subset of patients. Gain-of-function ...
Cited by 42 - Related articles - Find@The Christie - BL Direct - All 3 versions

Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis

JH Butterfield - Acta haematologica, 2000 - content.karger.com
Hypereosinophilic syndromes (HES) and systemic mastocytosis (SMCD) are heterogeneous disorders with clinical symptoms from local and remote effects of excessive proliferation of eosinophils and mast cells, respectively. Interferon α (IFN-α), alone or in combination with ...
Cited by 44 - Related articles - The Christie Online Journals - BL Direct - All 6 versions

Mastocytosis: current concepts in diagnosis and treatment

L Escribano, C Akin, M Castells, A Orfao... - Annals of hematology, 2002 - Springer
... cutaneous disease, but only in symptomatic cases Diffuse cutaneous mastocytosis € bullae Avoidance ... match is available Consider splenectomy Smoldering systemic mastocytosis Consider interferon ... Rapidly progressive aggressive mastocytosis or mast cell leukemia Watch for ...
Cited by 110 - Related articles - Find@The Christie - BL Direct - All 5 versions

Treatment of systemic mast cell disorders

AS Worobec - Hematology/oncology clinics of North America, 2000 - Elsevier
... Treatment of refractory hypotension and shock requires fluid resuscitative measures and additional pharmacologic intervention. ... 1:10,000 epinephrine infusion (up to 4–10 μg/min in adults and 0.1μg/kg/min in children) is generally recommended as first-line therapy. ...
Cited by 94 - Related articles - BL Direct - All 5 versions

Treatment of cutaneous mastocytosis

K Wolff - International archives of allergy and immunology, 2002 - content.karger.com
... Smith ML, Orton PW, Chu H, Weston WL: Photochemotherapy of dominant, diffuse cutaneous mastocytosis. ... Godt O, Proksch E, Streit V, Christophers E: Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis. ...
Cited by 34 - Related articles - BL Direct - All 4 versions
Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis

A Tefferi... - International journal of hematology, 2004 - Springer
Abstract Primary (nonreactive) eosinophilia is operationally classified as either a “clonal” or an “idiopathic” process. Clonal eosinophilia stipulates the presence of cytogenetic, molecular, or bone marrow histologic evidence of acute leukemia or a chronic myeloid ...
Cited by 23 - Related articles- Lancashire Teaching Hospitals- Find@The Christie - BL Direct - All 6 versions

Pathogenesis, clinical features, and treatment advances in mastocytosis

A Pardanani, C Akin... - Best Practice & Research Clinical ...., 2006 - Elsevier
... been identified in systemic mastocytosis as well as in mast cell leukemia (MCL). ... Eosinophilia commonly accompanies systemic mastocytosis (in 20–40% of cases) [78], [79], [80]... common is urticaria pigmentosa (UP); the others being diffuse cutaneous mastocytosis (DCM) and ...
Cited by 57 - Related articles- Lancashire Teaching Hospitals- Find@The Christie - All 7 versions

Treatment of systemic mastocytosis.

TM Wilson, DD Metcalfe, J Robyn - Immunology and allergy clinics ...., 2006 - ukpmc.ac.uk
It is an exciting time in the treatment of systemic mastocytosis. Major advances in the past 2 decades have helped to define the molecular abnormalities associated with this disease and to delineate pathways involved in its pathogenesis. This has directly translated into ...
Cited by 14 - Related articles - Cached- Lancashire Teaching Hospitals- Find@The Christie - All 5 versions

Mastocytosis: current treatment concepts

AS Worobec... - International archives of allergy ...., 2002 - content.karger.com
... beneficial in addition to antihistamines [2, 3, 4], Urticaria pigmentosa (UP) and diffuse cutaneous mastocytosis (DCM) have ... mastocytosis with an associated clonal hematologic non-mast cell lineage disease, aggressive systemic mastocytosis and mast cell leukemia are at ...
Cited by 27 - Related articles - BL Direct - All 4 versions

Mastocytosis: pathology, genetics, and current options for therapy

P Valent, C Akin, W Sperr... - Leukemia & ...., 2005 - informahealthcare.com
... (ii) diffuse cutaneous mastocytosis (DCM); and (iii) mastocytoma of the skin [51,69,70]. ... SM-MPD – SM-HES – SM-CMML – SM-NHL Aggressive systemic mastocytosis ASM – Lymphadenopathic SM with eosinophilia Mast cell leukemia MCL – Aleukemic MCL ...
Cited by 140 - Related articles- Lancashire Teaching Hospitals- Find@The Christie - All 9 versions